CapForce 

€2.9
0
+€0.13+4.58% Monday 20:00

Statistics

Day High
4.5
Day Low
0.43
52W High
4.5
52W Low
0.43
Volume
1,100
Avg. Volume
0
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

19MayExpected
Q2 2025
Next
-1.21
-0.87
-0.54
-0.21
Expected EPS
N/A
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 650.MU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Guardant Health
GH
Mkt Cap10.31B
Guardant Health, Inc. specializes in liquid biopsies and cancer diagnostics, directly competing with Opgen's diagnostic solutions for detecting pathogens and antibiotic resistance genes.
Illumina
ILMN
Mkt Cap18.49B
Illumina, Inc. provides sequencing and array-based solutions for genetic analysis, competing in the broader market of genomic analysis where Opgen also operates.
Qiagen NV
QGEN
Mkt Cap8.43B
Qiagen N.V. offers sample to insight solutions including infectious disease diagnostics, directly competing with Opgen's focus on molecular diagnostics.
Thermo Fisher Scientific
TMO
Mkt Cap184.37B
Thermo Fisher Scientific Inc. offers a wide range of diagnostics and research solutions, including those for infectious disease, competing with Opgen's diagnostic products.
Pacific Biosciences of California
PACB
Mkt Cap404.68M
Pacific Biosciences of California, Inc. provides sequencing systems that compete with Opgen's genomic analysis technologies.
Intellia Therapeutics
NTLA
Mkt Cap1.59B
Intellia Therapeutics, Inc. is involved in CRISPR technology for genetic editing, which could compete with Opgen's genomic approaches for diagnostics and treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.49B
BioMarin Pharmaceutical Inc. develops and commercializes innovative biopharmaceuticals, potentially competing with Opgen's treatments and diagnostics in genetic diseases.
Adaptive Biotechnologies
ADPT
Mkt Cap1.97B
Adaptive Biotechnologies Corp. focuses on the immune-driven medicine space, including diagnostics that could compete with Opgen's offerings in infection and resistance detection.

About

CapForce Inc., a precision medicine company, develops and commercializes molecular microbiology solutions for life threatening infectious diseases in the United States and internationally. The company's products include Unyvero application cartridges, Unyvero systems, Acuitas AMR Gene Panel test products, and SARS CoV-2 test kits. It also provides laboratory services; collaboration services, including funded software arrangements; and license arrangements services. In addition, the company offers listing sponsorship and consultancy services. CapForce Inc. was formerly known as OpGen, Inc. and changed its name to CapForce Inc. in February 2026. CapForce Inc. was incorporated in 2001 and is based in Clarksburg, Maryland.
Show more...
CEO
Mr. Christian-Laurent Benoit Bonte
Employees
1
Country
United States
ISIN
US68373L5057

Listings

0 Comments

Share your thoughts

FAQ

What is CapForce stock price today?
The current price of 650.MU is €2.9 EUR — it has increased by +4.58% in the past 24 hours. Watch CapForce stock price performance more closely on the chart.
What is CapForce stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange CapForce stocks are traded under the ticker 650.MU.
Is CapForce stock price growing?
650.MU stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year CapForce has showed a +0% increase.
When is the next CapForce earnings date?
CapForce is going to release the next earnings report on May 19, 2026.
How many employees does CapForce have?
As of April 13, 2026, the company has 1 employees.
In which sector is CapForce located?
CapForce operates in the Other sector.
When did CapForce complete a stock split?
CapForce has not had any recent stock splits.
Where is CapForce headquartered?
CapForce is headquartered in Clarksburg, United States.